Anti-CXCR3 Antibody Picoband® Fluoro594 Conjugated

Chemokine receptor CXCR3 is a Galphai protein-coupled receptor in the CXC chemokine receptor family. Other names for CXCR3 are G protein-coupled receptor 9 (GPR9) and CD183. It is mapped to Xq13.1. CXCR3 is expressed on malignant B cells from chronic lymphoproliferative disorders, particularly in patients with CLL, and represents a fully functional receptor involved in chemotaxis of malignant B lymphocytes. It is found that in the absence of known etiologic agents, CXCR3 represents a novel target for therapeutic interference early in type 1 diabetes. CXCR3 signaling is associated with MG pathogenesis and proposed that and CXCR3 may serve as novel drug targets to treat MG. CXCR3A and CXCR3B are involved in the chemotactic and vascular effects of CXCL4L1.

C-X-C chemokine receptor type 3; CXC-R3; CXCR-3; CKR-L2; G protein-coupled receptor 9; Interferon-inducible protein 10 receptor; IP-10 receptor; CD183; CXCR3; GPR9

E.coli-derived human CXCR3 recombinant protein (Position: M1-L368) . Human CXCR3 shares 86% amino acid (aa) sequence identity with both mouse and rat CXCR3.

Isoform 1 and isoform 2 are mainly expressed in heart, kidney, liver and skeletal muscle. Isoform 1 is also expressed in placenta. Isoform 2 is expressed in endothelial cells. Expressed in T-cells (at protein level) . .

Atherosclerosis, Calcium Signaling, Cardiovascular, Chemokines, G Protein Signaling, Immunology, Innate Immunity, Signal Transduction, Signaling Pathway, Vascular Inflammation

Isoform 1: Receptor for the C-X-C chemokine CXCL9, CXCL10 and CXCL11 and mediates the proliferation, survival and angiogenic activity of human mesangial cells (HMC) through a heterotrimeric G-protein signaling pathway (PubMed:12782716) . Binds to CCL21. Probably promotes cell chemotaxis response. .

1. Trentin, L., Agostini, C., Facco, M., Piazza, F., Perin, A., Siviero, M., Gurrieri, C., Galvan, S., Adami, F., Zambello, R., Semenzato, G. The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. J. Clin. Invest. 104: 115-121, 1999. 2. Frigerio, S., Junt, T., Lu, B., Gerard, C., Zumsteg, U., Hollander, G. A., Piali, L. Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. Nature Med. 8: 1414-1420, 2002. 3. Feferman, T., Maiti, P. K., Berrih-Aknin, S., Bismuth, J., Bidault, J., Fuchs, S., Souroujon, M. C. Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. J. Immun. 174: 5324-5331, 2005. 4. Struyf, S., Salogni, L., Burdick, M. D., Vandercappellen, J., Gouwy, M., Noppen, S., Proost, P., Opdenakker, G., Parmentier, M., Gerard, C., Sozzani, S., Strieter, R. M., Van Damme, J. Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. Blood 117: 480-488, 2011.